198 related articles for article (PubMed ID: 33076776)
81. Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given.
Pace-Asciak PZ; Payne RJ; Eski SJ; Walfish P; Damani M; Freeman JL
Arch Otolaryngol Head Neck Surg; 2007 Sep; 133(9):870-3. PubMed ID: 17875852
[TBL] [Abstract][Full Text] [Related]
82. Stunning phenomenon after a radioactive iodine- ¹³¹I diagnostic whole-body scan: Is it really a point of clinical consideration?
Amin A; Amin M; Badwey A
Nucl Med Commun; 2013 Aug; 34(8):771-6. PubMed ID: 23708870
[TBL] [Abstract][Full Text] [Related]
83. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
84. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
85. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer.
Ito S; Iwano S; Kato K; Naganawa S
Ann Nucl Med; 2018 Jul; 32(6):418-424. PubMed ID: 29766463
[TBL] [Abstract][Full Text] [Related]
86. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
[TBL] [Abstract][Full Text] [Related]
87. Use of radioiodine-131 scan to measure influence of surgical discipline, practice, and volume on residual thyroid tissue after total thyroidectomy for differentiated thyroid carcinoma.
Song JSA; Moolman N; Burrell S; Rajaraman M; Bullock MJ; Trites J; Taylor SM; Rigby MH; Hart RD
Head Neck; 2018 Oct; 40(10):2129-2136. PubMed ID: 29756327
[TBL] [Abstract][Full Text] [Related]
88. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
89. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
Hodgson DC; Brierley JD; Tsang RW; Panzarella T
Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
[TBL] [Abstract][Full Text] [Related]
90. Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis.
Piccardo A; Trimboli P; Bottoni G; Giovanella L
J Nucl Med; 2020 Dec; 61(12):1730-1735. PubMed ID: 32332146
[TBL] [Abstract][Full Text] [Related]
91. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
92. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
93. Technetium-99m-pertechnetate whole-body SPET/CT scan in thyroidectomized differentiated thyroid cancer patients is a useful imaging modality in detecting remnant thyroid tissue, nodal and distant metastases before
Lou K; Gu Y; Hu Y; Wang S; Shi H
Hell J Nucl Med; 2018; 21(2):121-124. PubMed ID: 30089313
[TBL] [Abstract][Full Text] [Related]
94. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
95. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease.
Donovan PJ; McLeod DS; Little R; Gordon L
Eur J Endocrinol; 2016 Dec; 175(6):595-603. PubMed ID: 27634939
[TBL] [Abstract][Full Text] [Related]
96. Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer.
Zanocco K; Kaltman DJ; Wu JX; Fingeret A; Heller KS; Lee JA; Yeh MW; Sosa JA; Sturgeon C
Ann Surg Oncol; 2018 Apr; 25(4):949-956. PubMed ID: 29417402
[TBL] [Abstract][Full Text] [Related]
97. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
98. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.
Van Nostrand D
Thyroid; 2009 Dec; 19(12):1381-91. PubMed ID: 20001720
[TBL] [Abstract][Full Text] [Related]
99. Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study.
Sawka AM; Straus S; Gafni A; Meiyappan S; David D; Rodin G; Brierley JD; Tsang RW; Thabane L; Rotstein L; Ezzat S; Goldstein DP
Support Care Cancer; 2012 Mar; 20(3):641-5. PubMed ID: 22072050
[TBL] [Abstract][Full Text] [Related]
100. Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Zhu Y; Liu K; Wang K; Peng L
Front Endocrinol (Lausanne); 2022; 13():909333. PubMed ID: 35909569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
